A Phase 4 interventional study of Labetalol and Magnesium Sulfate in Postoperative Pain and Cholelithiasis, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Assiut University · Phase 4, Interventional, and Treatment
Laparoscopic cholecystectomy (gallbladder removal) is one of the most common abdominal operations performed worldwide. Despite its minimally invasive approach, up to half of patients experience notable postoperative pain, which often requires opioid painkillers. Reducing perioperative opioid consumption through non-opioid medications helps minimize opioid-related side effects, improve comfort, and enhance postoperative recovery.
The primary purpose of this clinical trial is to compare the pain-relieving and opioid-sparing effects of three intravenous medications (labetalol, magnesium sulfate, and lidocaine) administered during elective laparoscopic cholecystectomy under general anesthesia.
Adult participants aged 18 to 60 years will be randomly assigned to one of three parallel groups:
The main outcome measured is total perioperative opioid consumption during surgery and throughout the first 24 postoperative hours. Investigators will also assess hemodynamic parameters (heart rate and blood pressure), blood oxygen levels, postoperative pain intensity scores, surgeon satisfaction, and the occurrence of any adverse effects.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
This study's planned enrollment of 90 is above the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Assiut University is the lead sponsor of 4,916 studies on the registry; 2,113 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants receive an initial loading dose of labetalol (0.25 mg/kg) diluted in 100 mL normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous intravenous infusion of 0.5-1 mg/kg/h until the end of the surgical procedure.
Drug: Labetalol
Participants receive an initial loading dose of magnesium sulfate (50 mg/kg) diluted in 100 mL normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous intravenous infusion of 25 mg/kg/h until the end of the surgical procedure.
Drug: Magnesium Sulfate
Participants receive an initial loading dose of lidocaine (1.5-2 mg/kg) diluted in 100 mL normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous intravenous infusion of 2 mg/kg/h until the end of the surgical procedure.
Drug: Lidocaine
Administered intravenously with an initial loading dose of 0.25 mg/kg diluted in 100 mL of 0.9% normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous maintenance infusion of 0.5-1.0 mg/kg/h until completion of the surgical procedure.
Administered intravenously with an initial loading dose of 50 mg/kg diluted in 100 mL of 0.9% normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous maintenance infusion of 25 mg/kg/h until completion of the surgical procedure.
Administered intravenously with an initial loading dose of 1.5-2.0 mg/kg diluted in 100 mL of 0.9% normal saline infused over 15 minutes prior to induction of general anesthesia, followed by a continuous maintenance infusion of 2.0 mg/kg/h until completion of the surgical procedure.
Total 24-Hour Opioid Consumption
Cumulative amount of intraoperative and postoperative rescue opioids administered, converted to intravenous morphine milligram equivalents (mg).
Time frame: 24 hours postoperatively
No study locations are listed for this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University